Kisspeptin Administration Subcutaneously to Patients With IHH
Status:
Recruiting
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
We are recruiting men and women with Idiopathic Hypogonadotropic Hypogonadism (IHH).
Kisspeptin will be administered subcutaneously (SC) for 2-weeks in a pulsatile fashion.
Ultrasound monitoring of ovarian follicular growth (for women) and frequent blood sampling
(q10 minutes for up to 70 minutes) will be performed to assess the physiologic response to
kisspeptin over time.